These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8185353)

  • 21. Adjuvant chemotherapy for non-organ confined bladder transitional cell carcinoma.
    Abi-Aad AS
    Acta Urol Belg; 1996 May; 64(2):35-7. PubMed ID: 8701808
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
    De Santis M; Bachner M
    Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of advanced bladder cancer.
    Hall RR; Roberts JT
    Prog Clin Biol Res; 1989; 303():525-31. PubMed ID: 2675009
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
    Matsumoto K
    Int J Urol; 2008 Oct; 15(10):949-50. PubMed ID: 19138292
    [No Abstract]   [Full Text] [Related]  

  • 26. Cisplatin and medium dose methotrexate in advanced transitional cell carcinoma of the urinary tract.
    Fosså SD; Sager EM; Hosbach G; Waehre H; Ous S
    Scand J Urol Nephrol; 1990; 24(3):199-204. PubMed ID: 2237296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder.
    Russell PJ; Raghavan D; Philips J; Gregory P
    Prog Clin Biol Res; 1988; 260():167-81. PubMed ID: 3362878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of the efficacy of intravesical cisplatin in superficial bladder tumors].
    Ojea A; Nogueira March JL; Figueiredo L; Jamardo D; Pérez Villanueva J
    Actas Urol Esp; 1984; 8(3):217-20. PubMed ID: 6540971
    [No Abstract]   [Full Text] [Related]  

  • 30. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
    Matveev BP; Figurin KM
    Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Chauvet B; Félix-Faure C; Davin JL; Berger C; Vincent P; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
    Fujita K; Murayama T; Sayama T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract]   [Full Text] [Related]  

  • 35. [Intraarterial chemotherapy with bladder preservation in patients with invasive bladder carcinoma].
    Shiba M; Takatera H; Fujii T; Tokizane T; Shimizu K; Tushima J
    Hinyokika Kiyo; 2004 Jan; 50(1):15-9. PubMed ID: 15032009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
    Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic factors of urinary bladder carcinoma].
    vom Dorp F; Jaeger T; Schmidt K; Siffert W; Rübben H
    Urologe A; 2007 Sep; 46(9):1151. PubMed ID: 17641868
    [No Abstract]   [Full Text] [Related]  

  • 39. [Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?].
    Housset M; Dufour B; Durdux C; Chrétien Y; Méjean A; Baillet F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():67s-72s. PubMed ID: 9749082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
    Dinney CP; Parker C; Dong Z; Fan D; Eve BY; Bucana C; Radinsky R
    Clin Cancer Res; 1997 Feb; 3(2):161-8. PubMed ID: 9815668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.